This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

55/100

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Long-term cohort studies

Topic: Brain proteins, microglia and lab models

Background Previous publications indicate that Alzheimer's Disease (AD) related cortical atrophy may develop in asymmetric patterns, with accentuation of the left hemisphere. Since fluorodeoxyglucose positron emission tomography (FDG PET) measurements of the regional cerebral metabolic rate of glucose (rCMRgl) provide a sensitive and specific marker of neurodegenerative disease progression, we sought to investigate the longitudinal pattern of rCMRgl in amyloid-positive persons with mild cognitive impairment (MCI) and dementia, hypothesizing asymmetric declines of cerebral glucose metabolism. Methods Using florbetapir PET and cerebrospinal fluid (CSF) measures to define amyloid-β (Aβ) positivity, 40 Aβ negative (Aβ-) cognitively unimpaired controls (CU; 76 ± 5y), 76 Aβ positive (Aβ+) persons with MCI (76 ± 7y) and 51 Aβ + persons with probable AD dementia (75 ± 7y) from the AD Neuroimagin

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Weise, C. M., Chen, K., Chen, Y., Kuang, X., Savage, C. R., Reiman, E. M., et al. (2018). Left lateralized cerebral glucose metabolism declines in amyloid-β positive persons with mild cognitive impairment. NeuroImage. Clinical. https://doi.org/10.1016/j.nicl.2018.07.016

Vancouver

Weise CM, Chen K, Chen Y, Kuang X, Savage CR, Reiman EM, et al. Left lateralized cerebral glucose metabolism declines in amyloid-β positive persons with mild cognitive impairment. NeuroImage. Clinical. 2018. doi:10.1016/j.nicl.2018.07.016. PMID: 30101060.

BibTeX

@article{weise2018-30101060,
  author  = {Weise, C. M. and Chen, K. and Chen, Y. and Kuang, X. and Savage, C. R. and Reiman, E. M. and {Alzheimer's Disease Neuroimaging Initiative}},
  title   = {{Left lateralized cerebral glucose metabolism declines in amyloid-β positive persons with mild cognitive impairment}},
  journal = {NeuroImage. Clinical},
  year    = {2018},
  doi     = {10.1016/j.nicl.2018.07.016},
  pmid    = {30101060},
  url     = {https://doi.org/10.1016/j.nicl.2018.07.016}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

Key findings

Since fluorodeoxyglucose positron emission tomography (FDG PET) measurements of the regional cerebral metabolic rate of glucose (rCMRgl) provide a sensitive and specific marker of neurodegenerative disease progression, we sought to investigate the longitudinal pattern of rCMRgl in amyloid-positive persons with mild cognitive impairment (MCI) and dementia, hypothesizing asymmetric declines of cerebral glucose metabolism.
Methods Using florbetapir PET and cerebrospinal fluid (CSF) measures to define amyloid-β (Aβ) positivity, 40 Aβ negative (Aβ-) cognitively unimpaired controls (CU; 76 ± 5y), 76 Aβ positive (Aβ+) persons with MCI (76 ± 7y) and 51 Aβ + persons with probable AD dementia (75 ± 7y) from the AD Neuroimaging Initiative (ADNI) were included in this study with baseline and 2-year follow-up FDG PET scans.
The degree of lateralization of longitudinal rCMRgl declines in subjects with Aβ + MCI and AD in comparison with Aβ- CU were statistically quantified via bootstrapped lateralization indices [(LI); range - 1 (right) to 1 (left)].
Results Compared to Aβ- CU, Aβ + MCI patients showed marked left hemispheric lateralization (LI: 0.78).

Why it matters

This longitudinal study used FDG PET to look at patterns of cerebral glucose metabolism in amyloid-positive people with mild cognitive impairment and dementia. It describes a marker of disease progression, not a treatment, cure or prevention.

Study details

Study designlongitudinal study
Evidence strengthModerate

How this study scored 55/100

Published in a peer-reviewed journal, and it is a longitudinal study following the same people over time. Scored zero for sample size, effect reported, studied in people and randomised / blinded because the record does not state it.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (NeuroImage. Clinical)
Journal's citation record	1 / 4	NeuroImage Clinical: journal h-index 133 (OpenAlex, 2026-10-29)
Study design	7 / 12	A longitudinal study following the same people over time
Strength of evidence	3 / 5	Rated “moderate” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	2 / 5	2018 — within 10 year(s) of the newest study here
Sample size	0 / 4	Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	0 / 3	Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomised / blinded	0 / 2	No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	4 / 7	Cited 95 times (OpenAlex, 2026-10-10)
Citations per year	3 / 5	9.5 citations a year over 10 year(s) since 2018
Impact for its field and year	3 / 6	Cited 5.2× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	2 / 6	Cited by 5 other studies in this library
Still being cited	2 / 4	Cited 35 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	4 / 4	Last-listed author Eric M. Reiman: h-index 151 (OpenAlex, whole career)
Institution's track record	1 / 3	University of Arizona: institution h-index 1,336 (OpenAlex)
Multi-centre collaboration	2 / 3	OpenAlex lists 8 institution(s) in 2 countries
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 30101060)
Free to read	2 / 2	Free to read
Total	55 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 14.

Later studies that cite this one

5 studies in the alzhub library list this one in their references.

Related studies in Long-term cohort studies

Also tagged “precursor”

1,339 studies in the library carry the topic tag “precursor”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,339 tagged studies.

Similar studies

More on Long-term cohort studies

See all studies in Long-term cohort studies →